GT Biopharma (GTBP) Gains from Investment Securities (2022 - 2026)
GT Biopharma (GTBP) posted quarterly Gains from Investment Securities of -$11000.0 for Q1 2026, up 91.27% year-over-year from -$5751.0 in Q1 2025, and down 466.67% quarter-over-quarter from $3000.0 in Q4 2025.
GT Biopharma (GTBP) Gains from Investment Securities (2022 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Gains from Investment Securities for 5 consecutive years, with -$11000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 91.27% year-over-year to -$11000.0; the TTM figure through Mar 2026 stood at -$126000.0 (down 116.07% YoY), while the FY2025 annual figure was -$241000.0, down 195.63% from the prior year.
- Gains from Investment Securities fell to -$11000.0 in Q1 2026 per GTBP's latest filing, from $3000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.1 million in Q4 2024 and bottomed at -$2.9 million in Q1 2023.
- Historically, Gains from Investment Securities has averaged -$289176.5 across 5 years, with a median of -$58000.0 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities plunged 27640.0% — and 2024, when it surged 112300.0%.
- GT Biopharma's Gains from Investment Securities stood at -$38000.0 in 2022, then soared by 97.37% to -$1000.0 in 2023, then soared by 112300.0% to $1.1 million in 2024, then plunged by 99.73% to $3000.0 in 2025, then plunged by 466.67% to -$11000.0 in 2026.
- Business Quant data shows GTBP's Gains from Investment Securities at -$11000.0 in Q1 2026, $3000.0 in Q4 2025, and -$232000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11,000.00 |
| Mar 31, 2026 | -11,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | -232,000.00 |
| Sep 30, 2025 | -232,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Jun 30, 2025 | 114,000.00 |
| Mar 31, 2025 | -126,000.00 |
| Mar 31, 2025 | -126,000.00 |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | -95,000.00 |
| Sep 30, 2024 | -95,000.00 |
| Jun 30, 2024 | -117,000.00 |
| Jun 30, 2024 | -117,000.00 |
| Mar 31, 2024 | -658,000.00 |
| Mar 31, 2024 | -658,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |